| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 12,768 | 23,194 | 84,929 | 9,216 |
| Research and development | 36,678 | 30,653 | 32,190 | 27,616 |
| General and administrative | 9,065 | 8,095 | 8,703 | 8,127 |
| Total operating expenses | 45,743 | 38,748 | 40,893 | 35,743 |
| Loss from operations | -32,975 | -15,554 | 44,036 | -26,527 |
| Interest income | 2,746 | 3,068 | 3,439 | 2,892 |
| Foreign currency exchange (loss) gain, net | -29 | 1,390 | 173 | -153 |
| Gain on disposal of property and equipment | 0 | 0 | 59 | - |
| Total other income | 2,717 | 4,458 | 3,671 | 2,739 |
| Net (loss) income before income taxes | -30,258 | -11,096 | 47,707 | -23,788 |
| Income tax benefit (provision) | -3,177 | 1,199 | 822 | 71 |
| Net (loss) income | -27,081 | -12,295 | 46,885 | -23,859 |
| Unrealized gain on available-for-sale securities | - | - | 21 | -311 |
| Unrealized loss on available-for-sale securities | - | 97 | - | - |
| Provision for pension benefit obligation | 53 | 53 | 48 | 37 |
| Unrealized gain (loss) on available-for-sale securities | 73 | - | - | - |
| Comprehensive (loss) income | -26,955 | -12,339 | 46,912 | -23,511 |
| Basic | 82,397,753 | 82,186,768 | 82,148,719 | 82,011,670 |
| Weighted-average number of common shares used in computing net loss per share-diluted | 82,397,753 | 82,186,768 | 82,956,423 | 82,011,670 |
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)